Arvinas ARVN Vepdegestrant ARV-471 — Program-specific external expense

Similar metrics at other companies

RAPPPreclinical Programs External Expenses — Research And Development Expense

$4.29M+32.1%

IDYADarovasertib — External Clinical Development Expenses

$23.33M+1.4%

TNGXVopimetostat Direct Program Expenses-RD — Research And Development Expense

$9.33M+70.9%

IDYAIDE574 — External Clinical Development Expenses

$3.05M+375%

IDYAIDE034 — External Clinical Development Expenses

$6.81M+17,816%

IDYAIDE849 — External Clinical Development Expenses

$4.77M+1,026%

Questions, answered.

What is Arvinas's vepdegestrant ARV-471 — program-specific external expense?

Arvinas (ARVN) reported vepdegestrant ARV-471 — program-specific external expense of $8.9M in Q1 2026.

How has Arvinas's vepdegestrant ARV-471 — program-specific external expense changed year-over-year?

Arvinas's vepdegestrant ARV-471 — program-specific external expense decreased by 63.1% year-over-year, from $24.1M to $8.9M.

What is the long-term trend for Arvinas's vepdegestrant ARV-471 — program-specific external expense?

Over 2 years (2023 to 2025), Arvinas's vepdegestrant ARV-471 — program-specific external expense has grown at a -22.7% compound annual growth rate (CAGR), from $104.8M to $62.7M.

What does vepdegestrant ARV-471 — program-specific external expense mean?

This metric represents the direct external costs incurred for the research, development, and clinical trial activities associated with a specific therapeutic candidate. It captures outsourced expenditures such as contract research organization fees, clinical site costs, and manufacturing expenses dedicated to advancing a single drug program through the pipeline. Monitoring this spend provides insight into the capital intensity and resource allocation strategy for individual high-priority clinical assets.